David Veitch

FDA Approves Basilea’s ZEVTERA® for Severe Bacterial Infections, Including Pediatric Use

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for…

1 month ago

Basilea Pharmaceutica Celebrates Milestone Payment as Cresemba® Sales Soar in Asia Pacific and China

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) announced a significant milestone with a USD 1.25 million payment triggered by the…

2 months ago

Basilea’s Antifungal Cresemba Sales in Latin America Trigger Milestone Payment from Partner Knight Therapeutics

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) has announced that its partner Knight Therapeutics Inc. (TSX: GUD) exceeded the sales…

4 months ago

Basilea’s Antifungal Drug Cresemba Surpasses Sales Threshold in Asia Pacific, Triggering $1.25 Million Milestone Payment

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company dedicated to addressing severe bacterial and fungal infections, has announced that its…

6 months ago

Basilea Pharmaceutica Reports Strong H1 2023 Financial Results and Increases Full-Year Guidance

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced robust financial…

9 months ago